biotech · Alzheimer Disease · Major Depressive Disorder · CGTX
Cognition Therapeutics
COGNITION THERAPEUTICS INC
Cognition Therapeutics clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2500 Westchester Ave, Purchase, New York 10577, US
- Founded
- 2007
- Employees
- 32
- Programs
- 33
- Drugs
- 26
- Patents
- 12
Cognition Therapeutics projects
18 ClinicalTrials.gov programs sponsored by Cognition Therapeutics.
Cognition Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Active Comparator CT1812
COGNITION THERAPEUTICS INC
Age-Related Macular Degeneration
1 trial -
Active Treatment- CT1812 100 mg
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Autobiographical Memory Flexibility (MemFlex) training
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
C105
COGNITION THERAPEUTICS INC
Cognition Disorders
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer Disease
3 trials -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Dementia With Lewy Bodies
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Early Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Mild to Moderate Alzheimer's Disease
1 trial -
Dexmedetomidine
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Memory Flexibility Training
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
Oxytocin nasal spray
COGNITION THERAPEUTICS INC
Cold Exposure
1 trial -
Oxytocin nasal spray
COGNITION THERAPEUTICS INC
Oxidative Stress
1 trial -
Psilocybin
COGNITION THERAPEUTICS INC
Treatment Resistant Depression
1 trial -
The Modular Protocol for Mental Health
COGNITION THERAPEUTICS INC
Major Depressive Disorder
1 trial -
UCAB-CT-05
COGNITION THERAPEUTICS INC
Primary biliary cholangitis (PBC)
1 trial -
Vortioxetine
COGNITION THERAPEUTICS INC
Post-COVID-19 Condition
1 trial -
golexanolone
COGNITION THERAPEUTICS INC
Primary Biliary Cholangitis (PBC)
1 trial
Frequently asked questions
How many clinical projects does Cognition Therapeutics have?
18 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.